ANGLE reports encouraging results from Parsortix oesophageal cancer study
Oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis, partly due to late diagnosis
ANGLE PLC (LON:AGL) said that a study at the University Hospital Ghent, Belgium showed its liquid biopsy system Parsortix consistently harvested oesophageal cancer cells in patients suffering from the disease.
These are the first published results in this cancer type, said ANGLE, and means the Parsortix system is now validated in 24 cancer types in 28 independent cancer research centres located across 11 countries.
Researchers in Belgium utilised ANGLE s marker-independent Parsortix system to isolate epithelial circulating tumour cells (CTCs) in patients and then performed cell-based image analysis to compare cell morphology and characteristics.
About ANGLE plc www.angleplc.com ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE s proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins. ANGLE s cell separation technology is called the Parsortix ® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen, as being an intact cell they allow DNA, RNA and protein a
/PRNewswire/ The Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline report is expected to rise due to an increased prevalence rate of.